Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Myriad Genetics, Inc. < Previous 1 2 Next > What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk July 17, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing July 11, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN PSNL Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date July 09, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Earns 2024 Great Place To Work® Certification™ July 02, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election June 24, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries June 11, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen June 04, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool June 03, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications May 30, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN QGEN New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer May 16, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA May 07, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting May 23, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business May 07, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 April 30, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor April 17, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen April 16, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing April 09, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date March 21, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device March 20, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the February 27, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 February 27, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 February 21, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health February 15, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics February 01, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology January 30, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics January 18, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO January 09, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance December 21, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care December 20, 2023 From Myriad Genetics, Inc. Via GlobeNewswire Tickers MYGN < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.